Next Science Ltd
ASX:NXS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Beijing Aosaikang Pharmaceutical Co Ltd
SZSE:002755
|
CN |
|
Bryah Resources Ltd
ASX:BYH
|
AU |
|
Eastfield Resources Ltd
XTSX:ETF
|
CA |
|
Medley Inc
OTC:MDLYF
|
JP |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| AU |
|
Next Science Ltd
ASX:NXS
|
42.4m AUD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.5T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
29.4B CHF |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
35.6B USD |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
99.8B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.3B USD |
Loading...
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
936.6B JPY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.8B USD |
Loading...
|
|
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
39.2B CNY |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.2B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37B CNY |
Loading...
|
Market Distribution
| Min | -14 949 200% |
| 30th Percentile | -526.4% |
| Median | -25.2% |
| 70th Percentile | 6.1% |
| Max | 145 596.9% |
Other Profitability Ratios
Next Science Ltd
Glance View
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Next Science Ltd is -39.7%, which is above its 3-year median of -60.4%.
Over the last 3 years, Next Science Ltd’s Operating Margin has increased from -112.9% to -39.7%. During this period, it reached a low of -112.9% on Jun 30, 2022 and a high of -39.7% on Jun 30, 2025.
